Supernus Pharmaceuticals, Inc.
SUPNNASDAQHealthcare● Active
$44.48
$-0.27(-0.60%)
Market Cap$2.6B
P/E Ratio—
52W High$59.68
52W Low$30.83
Supernus Pharmaceuticals, Inc. (SUPN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SUPN · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.72B | $0.66B | $0.61B | $0.67B | $0.58B |
| Cost of Revenue | $0.07B | $0.08B | $0.08B | $0.09B | $0.08B |
| Gross Profit | $0.64B | $0.58B | $0.52B | $0.58B | $0.50B |
| Gross Margin %(computed) | 89.63% | 88.23% | 86.21% | 86.93% | 87.05% |
| Operating Expenses | |||||
| R&D Expenses | $0.11B | $0.11B | $0.09B | $0.07B | $0.09B |
| G&A Expenses | $0.20B | $0.25B | $0.24B | $0.11B | $0.11B |
| Total Operating Expenses | $0.68B | $0.50B | $0.53B | $0.53B | $0.42B |
| Operating Income | ($0.04B) | $0.08B | ($0.01B) | $0.05B | $0.09B |
| Operating Margin %(computed) | -5.13% | 12.34% | -0.87% | 6.91% | 14.84% |
| Interest Income | $0.01B | $0.02B | $0.01B | $0.02B | $0.01B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.01B | $0.02B |
| Income Before Tax | ($0.05B) | $0.10B | $0.00B | $0.06B | $0.07B |
| Income Tax Expense | ($0.01B) | $0.02B | $0.00B | $0.00B | $0.02B |
| Net Income | ($0.04B) | $0.07B | $0.00B | $0.06B | $0.05B |
| Net Margin %(computed) | -5.36% | 11.16% | 0.22% | 9.10% | 9.21% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.68 | $1.34 | $0.02 | $1.13 | $1.01 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.05B | 0.05B | 0.05B |
| EBITDA | $0.04B | $0.18B | $0.09B | $0.15B | $0.13B |
| EBITDA Margin %(computed) | 5.92% | 26.94% | 14.82% | 22.98% | 22.28% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Supernus Pharmaceuticals, Inc. data
About Supernus Pharmaceuticals, Inc. (SUPN) Income Statement
Supernus Pharmaceuticals, Inc. (SUPN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SUPN reported revenue of $0.72B, gross profit of $0.64B (gross margin 89.63%), and net income of ($0.04B) — a net profit margin of -5.36%.
Frequently asked questions
SUPN · 4 questionsSupernus Pharmaceuticals, Inc. (SUPN) reported revenue of $0.72B for 2025, up 8.6% year-over-year.
SUPN revenueSUPN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09